Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management

JAMA

Volumn 279, Issue 24, 1998, Pages 1984-1991

  Hirsch, Martin S ^a,m   Conway, Brian ^b   D'Aquila, Richard T ^a   Johnson, Victoria A ^c   Brun Vézinet, Françoise ^d   Clotet, Bonaventura ^e   Demeter, Lisa M ^f   Hammer, Scott M ^a   Jacobsen, Donna M ^g   Kuritzkes, Daniel R ^h   Loveday, Clive ⁱ   Mellors, John W ^j   Vella, Stefano ^k   Richman, Douglas D ^l  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d BICHAT HOSPITAL   (France)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f UNIVERSITY OF ROCHESTER   (United States)

^g International AIDS Society USA   (Canada)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ ROYAL FREE HOSPITAL   (United Kingdom)

^j UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ASSAY; DRUG POTENCY; DRUG RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 17344390474     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.24.1984     Document Type: Review

References (92)

1. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
2. Havlir DV, Gamst A, Eastman S, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996;70:7894-7899.
3. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
4. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med. 1993;329:1065-1072.
5. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122:401-408.
6. Havlir DV, Hirsch M, Collier A, et al. Randomized trial of indinavir vs zidovudine/lamivudine vs indinavir/zidovudine/lamivudine maintenance therapy after induction of indinavir/zidovudine/lamivudine therapy. Presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 5, 1998; Chicago, Ill. Abstract LB16.
7. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994;121:263-268.
8. Eigen M. Viral quasispecies. Sci Am. 1993;269: 42-49.
9. Drake JW. Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A. 1993;90: 4171-4175.
10. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087-5094.
11. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1996;267:483-489.
12. Leigh Brown AJ, Richman DD. HIV-1: gambling on the evolution of drug resistance? Nature Med. 1997;3:268-271.
13. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
14. Perelson AS, Essunger P, Ho DD. Dynamics of HIV-1 and CD4 lymphocytes in vivo. AIDS. 1997; 11(suppl A):517-524.
15. Zhang LQ, Simmonds P, Ludlam CA, Leigh Brown AJ. Detection, quantitation, and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS. 1991; 5:675-681.
16. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses. 1994;10:1479-1488.
17. Nájera I, Holguín A, Quiñones-Mateu ME, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995;69:23-31.
18. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997;71:2059-2071.
19. de Jong MD, Schuurman R, Lange JM, Boucher CA. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antiviral Ther. 1996;1:34-42.
20. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in HIV-1 infection. Nature. 1995;373:117-122.
21. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-1171.
22. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine. Science. 1989;246:1155-1158.
23. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
24. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 1996;2:760-766.
25. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-1734.
26. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3:743-746.
27. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9-F14.
28. Gunthard H, Wong J, Ignacio C, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72: 2422-2428.
29. Wong JK, Hezareh M, Gunthard H, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
30. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
31. Schinazi RF, Larder BA, Mellors JW. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News. 1997; 5:129-142.
32. Lacey SF, Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′, 3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 1994;38:1428-1432.
33. Dueweke TJ, Pushkarskaya T, Poppe SM, et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A. 1993;90:4713-4717.
34. Lin PF, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994;170:1157-1164.
35. Demeter L, Griffith B, Bosch R, et al. HIV-1 drug susceptibilities during therapy with delavirdine + zidovudine, delavirdine + didanosine, or delavirdine + zidovudine + didanosine. Presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 4, 1998; Chicago, Ill. Abstract 706.
36. Condra JH, Holder DJ, Graham DJ, et al. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Fla. Antiviral Ther. 1997;2(suppl 5): Abstract 47.
37. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials - compensatory modulations of binding and activity. J Biol Chem. 1996;271:31957-31963.
38. Kleim J, Bender R, Kirsch R, Meichsner C, Paessens A, Rieb G. Mutational analysis of residue 190 of human immunodeficiency virus reverse transcriptase. Virology. 1994;200:696-701.
39. Boucher CA, van Leeuwen R, Kellam P, et al. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1993;37:1525-1530.
40. Chow Y, Hirsch MS, Merrill DP, et al. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature. 1993;361: 650-654.
41. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol. 1996;70:2146-2153.
42. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem. 1995;270:23605-23611.
43. Rubio A, Gomez-Cano M, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues (1993 versus 1997) among naive and pretreated HIV-infected patients in Spain (The Erase Study). Presented at: 5th Conference on Retroviruses and Opportunistic Infections; February 4, 1998; Chicago, Ill. Abstract 673.
44. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994;169:722-729.
45. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A. 1993;90:562-566.
46. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-1559.
47. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 1993;365:451-453.
48. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90: 5653-5656.
49. Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol. 1996;70:7171-7181.
50. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269: 696-699.
51. Bloor S, Kemp SD. Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Fla. Antiviral Ther. 1997;2(suppl 5):Abstract 11.
52. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis. 1997;176:398-405.
53. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to AZT and 3TC. J Virol. 1998;72:5093-5098.
54. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2:753-759.
55. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV-1 pol from clinical samples. AIDS Res Hum Retroviruses. In press.
56. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284-291.
57. Johnson VA. Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J Infect Dis. 1995;171(suppl 2): S140-S149.
58. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1993;37: 1095-1101.
59. Montaner JS, Singer J, Schechter MT, et al. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicenter Canadian AZT Trial. AIDS. 1993;7:189-196.
60. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995;171: 537-545.
61. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon alpha-A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infects Dis. 1991;164:646-655.
62. Mayers DL, McCutchan FE, Sangers-Buell EE, et al. Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr. 1992;5:749-759.
63. Richman DD, Johnson VA, Shirasaka T, O'Brien MC, Mitsuya H. Measurement of susceptibility of HIV-1 to antiviral drugs. In: Strober W, Shevach E, eds. Current Protocols in Immunology. New York, NY: Green Publishing Associates and Wiley-Interscience; 1993:12.9.1.
64. Parkin N, Whitcomb J, Smith D, et al. The use of rapid phenotypic HIV-1 drug resistance and susceptibility assay in analyzing the emergence of drug-resistant virus during triple combination therapy. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29, 1997; Toronto, Ontario. Abstract LB1.
65. Hertogs K, DeBethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998;42:269-276.
66. Kellam P, Larder BA. Recombinant virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 1994; 38:23-30.
67. Erice A, Mayers DL, Strike DG. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med. 1993; 328:1163-1165.
68. Yerly S, Rakik A, Kinloch-de Loes S, et al. Prevalence of transmission of zidovudine-resistant viruses in Switzerland. Schweiz Med Wochenschr. 1996;126:1845-1888.
69. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute HIV infection: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Fla. Antiviral Ther. 1997;2 (suppl 5):Abstract 103.
70. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997;175:1502-1506.
71. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
72. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep. 1998;47 (RR-05):43-82.
73. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA. In press.
74. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 1998;47:(RR-07): 1-33.
75. Rey D, Hughes M, Pi J, Winters M, Merigan TC, Katzenstein DA. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:203-208.
76. Mayers DL, Gallahan DL, Martin GJ, et al. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy. International Workshop on HIV Drag Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Florida, USA. Antiviral Ther. 1997;2(suppl 5):Abstract 80.
77. D'Aquila RT, Martinez-Picado J, Sutton L, Hoes Helfant A, Savara A, Kaplan J. Novel clonal analyses of resistance to HIV-1 RT and protease inhibitors. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Florida, USA. Antiviral Ther. 1997;2(suppl 5):Abstract 45.
78. Young B, Johnson S, Bakhtiari M, et al. Genotypic analysis of HIV-1 protease from patients failing highly active antiretroviral therapy: preliminary analysis: International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Fla. Antiviral Ther. 1997;2(suppl 5):Abstract 65.
79. Johnson VA, Nail CD, Hazelwood JD, et al. Multidrug-resistant HIV-1 isolates from patients with rising plasma viral burden during double or triple combination therapy in clinical practice. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, 25-28 June 1997, St Petersburg, Fla. Antiviral Ther. 1997;2(suppl 5): Abstract 77.
80. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
81. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 1997;11: F29-F33.
82. Harris M, Durakovic C, Rae S. Virologic response to indinavir/nevirapine/lamivudine correlates with indinavir trough concentrations. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 30, 1997; Toronto, Ontario. Abstract I-173.
83. Harris M, Durakovic C, Conway B, Fransen S, Shillington A, Montaner JSG. A pilot study of indinavir, nevirapine, and lamivudine in patients with advanced HIV disease. J Infect Dis. In press.
84. Sommadossi JP, Valantin MA, Zhou X, et al. Intracellular phosphorylation of stavudine and lamivudine correlates with their antiviral activity in naive and zidovudine-experienced HIV-infected patients. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 3, 1998; Chicago, Ill. Abstract 362.
85. Sommadossi JP, Zhou X, Moore J, et al. Impairment of stavudine phosphorylation in patients receiving a combination of zidovudine and stavudine. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, Ill. Abstract 3.
86. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses. 1996;12:107-115.
87. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine (ZDV) resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect Dis. 1995;171: 1172-1179.
88. Ogino MT, Dankner WM, Spector SA, et al. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J Pediatr. 1993;123:1-8.
89. Pizzo PA, Wilfert C. Antiretroviral therapy for infection due to human immunodeficiency virus in children. Clin Infect Dis. 1994;19:177-196.
90. Mellors JW, Hertogs K, Peeters F, et al. Susceptibility of clinical HIV-1 isolates to 1592U89. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. Abstract 687.
91. Lanier ER, Stone C, Griffin P, Thomas D, La-Fon S. Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral load response. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 4, 1998; Chicago, Ill. Abstract 686.
92. Centers for Disease Control and Prevention. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47 (RR-02):1-30.